series A financing

Xconomy names Xagenic to 2012’s Biotech Startup Class

January 18, 2013
Susanne Staer
Awards

MI spin-off company one of 30 listed in North America and the United Kingdom

Xconomy, a U.S.-based business news website, named Xagenic to its 2012 Biotech Startup Class.

Luke Timmerman‘s article, published December 3, 2012, sited Xagenic as one of only 30 “exciting biotech startups” to raise significant venture capital (at least $5 million) in the life sciences sector.

Xagenic, founded by Drs. Shana Kelley and Ted Sargent at the University of Toronto, was also the only Canadian company named to the list.

BioCentury Features Xagenic’s PCR-Based Infection-Diagnosis Technology

Xagenic, a MaRS Innovation spin-off company, was featured in the most recent issue of BioCentury. Here's an excerpt (the article only available to BioCentury subscribers): PCR-based diagnosis of infections can…

MaRS Innovation’s Lead Start-Up Completes $20 Million Series B

Xagenic’s financing round to test platform and first diagnostic assay, continue product development and begin FDA submission Toronto, ON (December 2, 2013) — MaRS Innovation’s first start-up company, Xagenic Inc.,…

Xagenic Raises $10 million in Series A Financing

TORONTO (January 30, 2012) – Xagenic Inc., a start-up company created by Dr. Shana Kelley, in partnership with MaRS Innovation, today reached a significant milestone by successfully completing series A financing totaling $10 million.

The financing comes from sources from the private and public sector including CTI Life Sciences Fund L.P., Qiagen N.V. and the Ontario Capital Growth Corporation through its Emerging Technologies Fund.

Xconomy names Xagenic to 2012’s Biotech Startup Class

MI spin-off company one of 30 listed in North America and the United Kingdom

BioCentury Features Xagenic’s PCR-Based Infection-Diagnosis Technology

MaRS Innovation’s Lead Start-Up Completes $20 Million Series B

Xagenic Raises $10 million in Series A Financing

Quick Links

Contact Us